Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426089 | 0.79 | PGR (0.31) | — | |
| SCHEMBL6874370 | 0.77 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL3836676 | 0.72 | MEN1 (0.35) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL15543777 | 0.69 | ALDH1A1 (0.37) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL6731777 | 0.69 | MEN1 (0.33) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL9712527 | 0.69 | ERN1 (0.42) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1591828 | 0.69 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL6060504 | 0.69 | ERN1 (0.42) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL29824002 | 0.69 | ERN1 (0.42) | MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL27702448 | 0.67 | ALDH1A1 (0.45) | MEN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| CN-102731381-B | The polysubstituted aryl of 6-()-4-aminopyridine formic acid esters and the purposes as herbicide thereof | 美国陶氏益农公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2060566-B1 | Poly-substituted aryls | DOW AGROSCIENCES LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9249160-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
| EP-1973881-B1 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-2060566-A1 | Poly-substituted aryls | Dow AgroSciences LLC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7498468-B2 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1973881-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | Dow Agrosciences LLC (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080051596-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045734-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-02-21 | — | — | US | disclosed |
| US-7314849-B2 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | CORTEVA AGRISCIENCE LLC | 2007-08-02 | — | — | US | disclosed |
| WO-2007082098-A2 | 6-(POLY-SUBSTITUTED ARYL)-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | MEN1 3296/4885ALDH1A1 3165/4885KMT2A 1060/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | MEN1 3296/4885ALDH1A1 3165/4885KMT2A 1060/4885 |
| US-20080045734-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | MEN1 4629/4885ALDH1A1 1065/4885KMT2A 263/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | MEN1 3296/4885ALDH1A1 3165/4885KMT2A 1060/4885 |
| US-20070179060-A1 | 6-(Poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | MEN1 4629/4885ALDH1A1 1065/4885KMT2A 263/4885 |
| US-20080051596-A1 | 6-(poly-substituted aryl)-4-aminopicolinates and their use as herbicides | AAAS, DDT, AADAC | MEN1 4629/4885ALDH1A1 1065/4885KMT2A 263/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | MEN1 3296/4885ALDH1A1 3165/4885KMT2A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.